The Impact of COVID-19 on Access to Parkinson's Disease Medication.
Parkinson's disease; COVID-19; epidemiology; access; medication
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
14
08
2020
accepted:
23
08
2020
pubmed:
30
8
2020
medline:
15
1
2021
entrez:
30
8
2020
Statut:
ppublish
Résumé
Many countries have implemented drastic measures to fight the COVID-19 pandemic. Restrictions and diversion of resources may have negatively affected patients with Parkinson's disease (PD). Our aim was to examine whether COVID-19 had an impact on access to PD medication by region and income. This study was conducted as part of a survey sent to members of the Movement Disorders Society focusing on access to PD medication globally. Of 346 responses, 157 (45.4%) agreed that COVID-19 had affected access to PD medication, while 189 (54.6%) disagreed. 22.8% of high-income and 88.9% of low-income countries' respondents agreed that access to PD medication was affected by COVID-19. 59% of all 'yes' respondents reported increased disability of patients as an impact. Access to PD medication is likely to have been affected by COVID-19 and result in deterioration of patients' symptomatic control. Resource-poor countries appear to be disproportionately affected compared to more affluent countries. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
Many countries have implemented drastic measures to fight the COVID-19 pandemic. Restrictions and diversion of resources may have negatively affected patients with Parkinson's disease (PD). Our aim was to examine whether COVID-19 had an impact on access to PD medication by region and income.
METHODS
This study was conducted as part of a survey sent to members of the Movement Disorders Society focusing on access to PD medication globally.
RESULTS
Of 346 responses, 157 (45.4%) agreed that COVID-19 had affected access to PD medication, while 189 (54.6%) disagreed. 22.8% of high-income and 88.9% of low-income countries' respondents agreed that access to PD medication was affected by COVID-19. 59% of all 'yes' respondents reported increased disability of patients as an impact.
CONCLUSIONS
Access to PD medication is likely to have been affected by COVID-19 and result in deterioration of patients' symptomatic control. Resource-poor countries appear to be disproportionately affected compared to more affluent countries. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2129-2133Subventions
Organisme : The Preventive Neurology Unit is funded by the Barts Charity
Pays : International
Informations de copyright
© 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
World Health Organisation. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020. Accessed July 24, 2020.
Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm 2017;124:901-905.
United Nations Statistics Division. UNSD - Methodology; 2020. https://unstats.un.org/unsd/methodology/m49/. Accessed July 24, 2020.
The World Bank. World Bank Country and Lending Groups; 2020. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups. Accessed July 24, 2020.
Bhidayasiri R, Virameteekul S, Kim J-M, Pal PK, Chung S-J. COVID-19: An early review of Its global impact and considerations for Parkinson's disease patient care. J Mov Disord 2020;13(2):105-114.
Antonini A, Leta V, Teo J, Chaudhuri KR. Outcome of Parkinson's disease patients affected by COVID-19. Mov Disord 2020;35(6):905-908. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267273/. Accessed July 24, 2020.
Fasano A, Cereda E, Barichella M, et al. COVID −19 in Parkinson's disease patients living in Lombardy, Italy. Mov Disord 2020;35(7):1089-1093. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300944/?report=abstract. Accessed July 24, 2020.
Helmich RC, Bloem BR. The Impact of the COVID-19 pandemic on Parkinson's disease: hidden sorrows and emerging opportunities. J Parkinsons Dis 2020;10(2):351-354. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242824/. Accessed July 24, 2020.
Brown EG, Chahine LM, Goldman SM, et al. The effect of the COVID-19 pandemic on people with Parkinson's disease. medRxiv. Cold Spring Harbor Laboratory Press; 2020. https://www.medrxiv.org/content/10.1101/2020.07.14.20153023v1. Accessed August 2, 2020.
Ghosh A, Gupta R, Misra A. Telemedicine for diabetes care in India during COVID19 pandemic and national lockdown period: guidelines for physicians. Diabetes Metab Syndr Clin Res Rev 2020;14(4):273-276. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129346/?report=abstract. Accessed July 24, 2020.
Mauro V, Lorenzo M, Paolo C, Sergio H. Treat all COVID 19-positive patients, but do not forget those negative with chronic diseases. Intern Emerg Med 2020;1-4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282471. Accessed July 24, 2020.
Benaque A, Gurruchaga MJ, Abdelnour C, et al. Dementia care in times of COVID-19: experience at Fundació ACE in Barcelona, Spain. J Alzheimer's Dis 2020;76(1):1-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369075/?report=abstract. Accessed 24 July 2020.
Schirinzi T, Cerroni R, Di Lazzaro G, et al. Self-reported needs of patients with Parkinson's disease during COVID-19 emergency in Italy. Neurol Sci 2020;41(6):1373-1375. https://ncbi.nlm.nih.gov/pmc/articles/PMC7196180/?report=abstract. Accessed July 24, 2020.
Zipprich HM, Teschner U, Witte OW, Schönenberg A, Prell T. Knowledge, attitudes, practices, and burden during the COVID-19 pandemic in people with Parkinson's disease in Germany. J Clin Med 2020;9(6):1643. https://www.mdpi.com/2077-0383/9/6/1643. Accessed July 24, 2020.
Prasad S, Holla VV, Neeraja K, et al. Parkinson's disease and COVID-19: perceptions and implications in patients and caregivers. Mov Disord 2020;35(6):912-914. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264599/. Accessed July 24, 2020.
Ben-Pazi H, Browne P, Chan P, et al. The promise of telemedicine for movement disorders: an interdisciplinary approach. Current Neurology and Neuroscience Reports 2018;18:26. https://doi.org/10.1007/s11910-018-0834-6
Schneider RB, Biglan KM. The promise of telemedicine for chronic neurological disorders: the example of Parkinson's disease. Lancet Neurol 2017;16(7):541-551. https://pubmed.ncbi.nlm.nih.gov/28566190/. Accessed July 24, 2020.
Dorsey ER, Deuel LM, Voss TS, et al. Increasing access to specialty care: a pilot, randomized controlled trial of telemedicine for Parkinson's disease. Mov Disord 2010;25(11):1652-1659. https://doi.org/10.1002/mds.23145
Abdolahi A, Scoglio N, Killoran A, Dorsey ER, Biglan KM. Potential reliability and validity of a modified version of the unified Parkinson's disease rating scale that could be administered remotely. Park Relat Disord 2013;19(2):218-221. http://www.prd-journal.com/article/S1353802012003847/fulltext. Accessed July 24, 2020.
Miele G, Straccia G, Moccia M, et al. Telemedicine in Parkinson's disease: how to ensure patient needs and continuity of care at the time of COVID-19 pandemic. Telemed e-Health 2020 Jul 13. https://www.liebertpub.com/doi/10.1089/tmj.2020.0184. Accessed July 24, 2020.
Bloem BR, Dorsey ER, Okun MS. The coronavirus disease 2019 crisis as catalyst for telemedicine for chronic neurological disorders. JAMA Neurology 2020;77(8):927-928. https://jamanetwork.com/journals/jamaneurology/fullarticle/2765073. Accessed July 24, 2020.
Papa SM, Brundin P, Fung VSC, et al. Impact of the COVID-19 pandemic on Parkinson's disease and movement disorders. Mov Disord 2020;35(5):711-715. https://doi.org/10.1002/mds.28067
Hemmerle AM, Herman JP, Seroogy KB. Stress, depression and Parkinson's disease. Exp Neurol 2012;233(1):79-86. https://pubmed.ncbi.nlm.nih.gov/22001159/. Accessed July 24, 2020.
Zach H, Dirkx MF, Pasman JW, Bloem BR, Helmich RC. Cognitive stress reduces the effect of levodopa on Parkinson's resting tremor. CNS Neurosci Ther 2017;23(3):209-215. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324662/?report=abstract. Accessed July 24, 2020.
Salari M, Zali A, Ashrafi F, et al. Incidence of anxiety in Parkinson's disease during the coronavirus disease (COVID −19) pandemic. Mov Disord 2020;35(7):1095-1096. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273007/. Accessed July 24, 2020.